AB0698 SYSTEMIC LUPUS ERYTHEMATOSUS OVER 80 YEARS OF AGE: A RETROSPECTIVE COHORT OF VERY LATE-ONSET IN A THIRD LEVEL HOSPITAL [PDF]
, 2023 Antía Crespo-Golmar +5 more
openalex +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Model Choice Matters for Age Inference on the Red Giant Branch [PDF]
arXivGalactic archaeology relies on accurate stellar parameters to reconstruct the galaxy's history, including information on stellar ages. While the precision of data has improved significantly in recent years, stellar models used for age inference have not improved at a similar rate.
arxiv
Laparoscopic surgery for colorectal cancer in patients over 80 years of age: the morbidity outcomes [PDF]
, 2017 Sang Woo Lim +2 more
openalex +1 more source
Health-related quality of life among community-dwelling people aged 80 years and over: a cross-sectional study in France [PDF]
, 2020 Isabelle Jalenques +4 more
openalex +1 more source
Clinical and epidemiological characterization of adults over the age of 80 with acute coronary syndrome [PDF]
, 2023 Álvaro Rodríguez +7 more
openalex +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
18IS THERE A NEED FOR ‘SPECIALISTS’ TO BECOME ‘GENERALISTS’? A SURVEY COMPARING HOSPITAL OUTCOMES IN OLDER PATIENTS AGED OVER 75 YEARS WHO ARE MANAGED BY GENERAL PHYSICIANS VERSUS THOSE AGED OVER 80 YEARS MANAGED BY OLDER PEOPLE'S MEDICINE PHYSICIANS (OPM) [PDF]
, 2017 G Dawson +3 more
openalex +1 more source
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source